Abstract
Bromodomain and extraterminal domain (BET) proteins are transcriptional co-activators through their effects on histone modification. Inhibitors that target BET proteins have therapeutic efficacy in mouse models of leukaemia and lymphoma through the suppression of MYC expression. William Lockwood and colleagues show that the BET inhibitor JQ1 also has antiproliferative effects in a subset of lung adenocarcinoma cell lines. Gene expression profiling indicates that this occurs through reduced expression of the transcription factor FOSL1. Thus, depending on the genes expressed, BET inhibitors might prove useful for the treatment of certain solid tumours.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
